Infliximaba | Remicade® | Anti-TNF | RA, PsA, AS | IV | |
Inflectra®b |
Remsimab |
| |
Etanercepta | Enbrel® | Anti-TNF | RA, PsA, AS | S/C | FBC and LFT monitoring |
Benepali®b |
| |
Adalimumaba | Humira® | Anti-TNF | RA, PsA, AS | S/C | Risk of TB reactivation |
| |
Certolizumab Pegol | Cimzia | Anti-TNF | RA, PsA, AS | S/C | |
| |
Golimumab | Simponi® | Anti-TNF | RA, PsA, AS | S/C | |
|
Tocilizumab | RoActemra | Anti-IL-6 | RA | IV or S/C | Lipid monitoring Reduced CRP response to infection |
|
Abatacept | Orencia® | Anti-CD28 | RA | IV or S/C | |
|
Rituximab | Mabthera | Anti-CD20 | RA | IV | Rarely can cause PML — alert specialist if neurological symptoms develop |